Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
JNJ-67856633 + Ibrutinib for Lymphoma and Leukemia
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing two drugs, JNJ-67856633 and ibrutinib, to find the safest and most effective dose for treating certain blood cancers. It targets patients with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), who may not respond well to standard treatments. These drugs work by blocking proteins that help cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service